Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles
Open Access
- 22 August 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (9) , 4676-4686
Abstract
In the present article, we describe a multimodal radiobioconjugate that contains a chemotherapeutic agent (doxorubicin, DOX), a β-emitter (198Au), and a guiding vector (trastuzumab, Tmab) for targeted therapy of cancers overexpressing HER2 receptors. To achieve this goal, radioactive gold nanoparticles (198AuNPs) with a mean diameter of 30 nm were synthesized and coated with a poly(ethylene glycol) (PEG) linker conjugated to DOX and monoclonal antibody (Tmab) via peptide bond formation. In vitro experiments demonstrated a high affinity of the radiobioconjugate to HER2 receptors and cell internalization. Cytotoxicity experiments performed using the MTS assay showed a significant decrease in the viability of SKOV-3 cells. A synergistic cytotoxic effect due to the simultaneous presence of DOX and 198Au was revealed after 48 h of treatment with 2.5 MBq/mL. Flow cytometry analysis indicated that DOX-198AuNPs-Tmab mainly induced cell cycle arrest in the G2/M phase and late apoptosis. Dose-dependent additive and synergistic effects of the radiobioconjugate were also shown in spheroid models. Ex vivo biodistribution experiments were performed in SKOV-3 tumor-bearing mice, investigating different distributions of the 198AuNPs-DOX and DOX-198AuNPs-Tmab after intravenous (i.v.) and intratumoral (i.t.) administration. Finally, in vivo therapeutic efficacy studies on the same animal model demonstrated very promising results, as they showed a significant tumor growth arrest up to 28 days following a single intratumoral injection of 10 MBq. Therefore, the proposed multimodal radiobioconjugate shows great potential for the local treatment of HER2+ cancers.Keywords
Funding Information
- Narodowe Centrum Nauki (2018/31/D/ST4/01488)
- European Cooperation in Science and Technology (CA 17140)
- European Social Fund Plus (POWR.03.02.00-00-I009/17-00)
This publication has 38 references indexed in Scilit:
- Targeting breast carcinoma with radioiodinated anti-HER2 NanobodyNuclear Medicine and Biology, 2013
- Role of Antibody-Mediated Tumor Targeting and Route of Administration in Nanoparticle Tumor Accumulation in VivoMolecular Pharmaceutics, 2012
- Laminin receptor specific therapeutic gold nanoparticles ( 198 AuNP-EGCg) show efficacy in treating prostate cancerProceedings of the National Academy of Sciences, 2012
- Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administrationEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor–bearing miceNanomedicine: Nanotechnology, Biology and Medicine, 2010
- Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in ratsBiomaterials, 2010
- Folate-Receptor-Targeted Delivery of Doxorubicin Using Polyethylene Glycol-Functionalized Gold NanoparticlesIndustrial & Engineering Chemistry Research, 2010
- Doxorubicin Exerts Cytotoxic Effects through Cell Cycle Arrest and Fas-Mediated Cell DeathPharmacology, 2009
- Current experience with mIBG therapy in combination with chemotherapy and radiosensitizersNuclear Medicine and Biology, 2008
- Nanomedicines and nanotoxicology: some physiological principlesOccupational Medicine, 2006